Suven Pharmaceuticals Share Price
Sector: Biotechnology & Drugs
You have to be logged in to add this to Watchlist.
Login or Register
1276.00 -3.50 (-0.27%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
1260.05
Today’s High
1281.5
52 Week Low
578.05
52 Week High
1358.75
1275.95 -3.60 (-0.28%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
1258.4
Today’s High
1284
52 Week Low
577
52 Week High
1353.95
Key Metrics
- Market Cap (In Cr) 32572.86
- Beta 1.66
- Div. Yield (%) 0
- P/B 15.88
- TTM P/E 122.75
- Peg Ratio -22.1
- Sector P/E 31.15
- D/E 0.02
- Open Price 1279.5
- Prev Close 1279.5
Suven Pharmaceuticals Analysis
Price Analysis
-
1 Week2.31%
-
3 Months31.32%
-
6 Month102.94%
-
YTD77.03%
-
1 Year115.63%
Risk Meter
- 38% Low risk
- 38% Moderate risk
- 38% Balanced Risk
- 38% High risk
- 38% Extreme risk
Recos
- Strong Sell
- Sell
- Hold
- Buy
- Strong Buy
Analysts' Views
- Ratings
- Current
- 1 W Ago
- 1 M Ago
- 3 M Ago
- Strong Buy
- 1
- 1
- 1
- 1
- Buy
- 0
- 0
- 0
- 0
- Hold
- 0
- 0
- 0
- 0
- Sell
- 0
- 0
- 0
- 0
- Strong Sell
- 0
- 0
- 0
- 0
- Total
- 1
- 1
- 1
- 1
Suven Pharmaceuticals News
Sunrest Lifescience, MT Educare & others hit 52 week low today ;Check the full list here?
4 min read . 05 Nov 2024Tilaknagar Industries, Aditya Birla Sun Life AMC & others hit 52 week high today ; Do you own any?
3 min read . 05 Nov 2024Stock market today: Experts recommend four stocks to buy or sell on Tuesday
5 min read . 22 Oct 2024Suven Pharmaceuticals Financials
- INCOME
- BALANCE SHEET
- Cashflow
- Period
- 2024
- Total Revenue
- 1051.35
- Selling/ General/ Admin Expenses Total
- 135.92
- Depreciation/ Amortization
- 54.6
- Other Operating Expenses Total
- 61.11
- Total Operating Expense
- 700.14
- Operating Income
- 351.22
- Net Income Before Taxes
- 405.67
- Net Income
- 300.28
- Diluted Normalized EPS
- 11.8
- Period
- 2024
- Total Assets
- 2254.09
- Total Liabilities
- 203.42
- Total Equity
- 2050.66
- Tangible Book Valueper Share Common Eq
- 78.12
- Period
- 2024
- Cashfrom Operating Activities
- 358.48
- Cashfrom Investing Activities
- -362.25
- Cashfrom Financing Activities
- -13.8
- Net Changein Cash
- -17.57
- Period
- 2023
- Total Revenue
- 1340.33
- Selling/ General/ Admin Expenses Total
- 196.86
- Depreciation/ Amortization
- 47.73
- Total Operating Expense
- 821.52
- Operating Income
- 518.81
- Net Income Before Taxes
- 559.73
- Net Income
- 411.29
- Diluted Normalized EPS
- 16.16
- Period
- 2023
- Total Assets
- 1965.74
- Total Liabilities
- 230.56
- Total Equity
- 1735.18
- Tangible Book Valueper Share Common Eq
- 65.72
- Period
- 2023
- Cashfrom Operating Activities
- 450.91
- Cashfrom Investing Activities
- -194.84
- Cashfrom Financing Activities
- -235.83
- Net Changein Cash
- 20.24
- Period
- 2022
- Total Revenue
- 1320.22
- Selling/ General/ Admin Expenses Total
- 179.96
- Depreciation/ Amortization
- 39.1
- Total Operating Expense
- 779.69
- Operating Income
- 540.53
- Net Income Before Taxes
- 667.59
- Net Income
- 453.8
- Diluted Normalized EPS
- 17.83
- Period
- 2022
- Total Assets
- 1829.59
- Total Liabilities
- 302.41
- Total Equity
- 1527.18
- Tangible Book Valueper Share Common Eq
- 59.9
- Period
- 2022
- Cashfrom Operating Activities
- 330
- Cashfrom Investing Activities
- -136.21
- Cashfrom Financing Activities
- -156.41
- Net Changein Cash
- 37.38
- Period
- 2021
- Total Revenue
- 1009.72
- Selling/ General/ Admin Expenses Total
- 142.84
- Depreciation/ Amortization
- 31.64
- Total Operating Expense
- 600.87
- Operating Income
- 408.84
- Net Income Before Taxes
- 467.67
- Net Income
- 362.34
- Diluted Normalized EPS
- 14.23
- Period
- 2021
- Total Assets
- 1474.47
- Total Liabilities
- 293.66
- Total Equity
- 1180.81
- Tangible Book Valueper Share Common Eq
- 46.28
- Period
- 2021
- Cashfrom Operating Activities
- 382.55
- Cashfrom Investing Activities
- -311.4
- Cashfrom Financing Activities
- -75.66
- Net Changein Cash
- -4.51
- Period
- 2020
- Total Revenue
- 833.79
- Selling/ General/ Admin Expenses Total
- 128.98
- Depreciation/ Amortization
- 23.86
- Other Operating Expenses Total
- 0
- Total Operating Expense
- 472.52
- Operating Income
- 361.27
- Net Income Before Taxes
- 404.51
- Net Income
- 317
- Diluted Normalized EPS
- 12.45
- Period
- 2020
- Total Assets
- 1172.81
- Total Liabilities
- 328.05
- Total Equity
- 844.76
- Tangible Book Valueper Share Common Eq
- 33.07
- Period
- 2020
- Cashfrom Operating Activities
- 415.95
- Cashfrom Investing Activities
- -421.53
- Cashfrom Financing Activities
- 6.37
- Net Changein Cash
- 0.79
- Period
- 2019
- Total Revenue
- 377.83
- Selling/ General/ Admin Expenses Total
- 60.89
- Depreciation/ Amortization
- 11.5
- Total Operating Expense
- 215.09
- Operating Income
- 162.74
- Net Income Before Taxes
- 157.87
- Net Income
- 109.27
- Diluted Normalized EPS
- 4.29
- Period
- 2019
- Total Assets
- 783.02
- Total Liabilities
- 192.73
- Total Equity
- 590.29
- Tangible Book Valueper Share Common Eq
- 23.08
- Period
- 2019
- Cashfrom Operating Activities
- 50.4
- Cashfrom Investing Activities
- -65.48
- Cashfrom Financing Activities
- 25.98
- Net Changein Cash
- 10.9
- Period
- 2024-09-30
- Total Revenue
- 257.72
- Selling/ General/ Admin Expenses Total
- 51.87
- Depreciation/ Amortization
- 16.96
- Other Operating Expenses Total
- 49.78
- Total Operating Expense
- 170.67
- Operating Income
- 87.05
- Net Income Before Taxes
- 99.5
- Net Income
- 82.21
- Diluted Normalized EPS
- 3.21
- Period
- 2024-09-30
- Total Assets
- 2505.56
- Total Liabilities
- 527.22
- Total Equity
- 1978.34
- Tangible Book Valueper Share Common Eq
- 67.05
- Period
- 2024-09-30
- Cashfrom Operating Activities
- 177.67
- Cashfrom Investing Activities
- -142.29
- Cashfrom Financing Activities
- -45.79
- Net Changein Cash
- -10.41
- Period
- 2024-06-30
- Total Revenue
- 230.69
- Selling/ General/ Admin Expenses Total
- 45.62
- Depreciation/ Amortization
- 13.4
- Other Operating Expenses Total
- 14.46
- Total Operating Expense
- 164.16
- Operating Income
- 66.53
- Net Income Before Taxes
- 83.09
- Net Income
- 60.77
- Diluted Normalized EPS
- 2.39
- Period
- 2024-06-30
- Period
- 2024-06-30
- Period
- 2024-03-31
- Total Revenue
- 252.93
- Selling/ General/ Admin Expenses Total
- 39.39
- Depreciation/ Amortization
- 17.25
- Other Operating Expenses Total
- 19.94
- Total Operating Expense
- 196.83
- Operating Income
- 56.1
- Net Income Before Taxes
- 70.85
- Net Income
- 53.37
- Diluted Normalized EPS
- 2.1
- Period
- 2024-03-31
- Total Assets
- 2254.09
- Total Liabilities
- 203.42
- Total Equity
- 2050.66
- Tangible Book Valueper Share Common Eq
- 78.12
- Period
- 2024-03-31
- Cashfrom Operating Activities
- 358.48
- Cashfrom Investing Activities
- -362.25
- Cashfrom Financing Activities
- -13.8
- Net Changein Cash
- -17.57
- Period
- 2023-12-31
- Total Revenue
- 219.82
- Selling/ General/ Admin Expenses Total
- 32.83
- Depreciation/ Amortization
- 12.75
- Other Operating Expenses Total
- 14.42
- Total Operating Expense
- 167.43
- Operating Income
- 52.39
- Net Income Before Taxes
- 65.47
- Net Income
- 46.75
- Diluted Normalized EPS
- 1.84
- Period
- 2023-12-31
- Period
- 2023-12-31
- Period
- 2023-09-30
- Total Revenue
- 231.05
- Selling/ General/ Admin Expenses Total
- 28.58
- Depreciation/ Amortization
- 11.89
- Other Operating Expenses Total
- 13.16
- Total Operating Expense
- 144.98
- Operating Income
- 86.07
- Net Income Before Taxes
- 105.41
- Net Income
- 79.56
- Diluted Normalized EPS
- 3.13
- Period
- 2023-09-30
- Total Assets
- 2119.77
- Total Liabilities
- 184.37
- Total Equity
- 1935.4
- Tangible Book Valueper Share Common Eq
- 73.59
- Period
- 2023-09-30
- Cashfrom Operating Activities
- 252.31
- Cashfrom Investing Activities
- -237.89
- Cashfrom Financing Activities
- -21.64
- Net Changein Cash
- -7.23
- Period
- 2023-06-30
- Total Revenue
- 347.55
- Selling/ General/ Admin Expenses Total
- 28.74
- Depreciation/ Amortization
- 12.54
- Other Operating Expenses Total
- 16.21
- Total Operating Expense
- 193.13
- Operating Income
- 154.42
- Net Income Before Taxes
- 163.94
- Net Income
- 120.59
- Diluted Normalized EPS
- 4.74
- Period
- 2023-06-30
- Period
- 2023-06-30
- Period
- 2023-03-31
- Total Revenue
- 369.36
- Selling/ General/ Admin Expenses Total
- 25.6
- Depreciation/ Amortization
- 11.96
- Other Operating Expenses Total
- 15.77
- Total Operating Expense
- 212.24
- Operating Income
- 157.12
- Net Income Before Taxes
- 166.21
- Net Income
- 123.97
- Diluted Normalized EPS
- 4.87
- Period
- 2023-03-31
- Total Assets
- 1965.74
- Total Liabilities
- 230.56
- Total Equity
- 1735.18
- Tangible Book Valueper Share Common Eq
- 65.72
- Period
- 2023-03-31
- Cashfrom Operating Activities
- 450.91
- Cashfrom Investing Activities
- -194.84
- Cashfrom Financing Activities
- -235.83
- Net Changein Cash
- 20.24
- Period
- 2022-12-31
- Total Revenue
- 353.77
- Selling/ General/ Admin Expenses Total
- 29.68
- Depreciation/ Amortization
- 12.24
- Other Operating Expenses Total
- 18.13
- Total Operating Expense
- 219.32
- Operating Income
- 134.46
- Net Income Before Taxes
- 146.08
- Net Income
- 107.72
- Diluted Normalized EPS
- 4.23
- Period
- 2022-12-31
- Period
- 2022-12-31
Forecast
Income Sheet (In Cr)
Net Income Vs Revenue
Returns Metrics (In Cr)
ROA Vs ROE
Forecast
Balance Sheet
Asset vs Liability
Forecast
Cash Flow
Operating vs Investing
Suven Pharmaceuticals Technical
Moving Average
SMA
- 5 Day1260.5
- 10 Day1278.21
- 20 Day1278.48
- 50 Day1230.62
- 100 Day1082.39
- 300 Day876.04
Suven Pharmaceuticals Peers
- Price
- Ratio
- Name
- Latest Price
- Change
- % Change
- 52W High
- 52W Low
- Mkt. Cap
- Ajanta Pharmaceuticals
- 2938.1
- -1.55
- -0.05
- 3485.75
- 1852.55
- 36994.99
- Syngene International
- 847.65
- -2.6
- -0.31
- 945.75
- 608
- 33971.38
- Suven Pharmaceuticals
- 1276
- -3.5
- -0.27
- 1358.75
- 578.05
- 32482.49
- Gland Pharma
- 1788.7
- 10.25
- 0.58
- 2220.95
- 1590
- 29461.77
- Laurus Labs
- 489.25
- 0.1
- 0.02
- 517.9
- 358.7
- 26368.9
- Name
- P/E (X)
- P/B (X)
- ROE %
- OPM
- Ajanta Pharmaceuticals
- 45.16
- 10.36
- 21.37
- 19.31
- Syngene International
- 65.62
- 8.01
- 14.56
- 16.22
- Suven Pharmaceuticals
- 107.58
- 15.88
- 27.91
- 33.21
- Gland Pharma
- 38.03
- 3.37
- 14.89
- 22.92
- Laurus Labs
- 162.98
- 6.41
- 20.68
- 12.83
Suven Pharmaceuticals Shareholding
Shareholding Pattern
Shareholding Trend
Shareholding(%) v/s Date
Corporate Actions
- Board Meeting
- AGM
- Dividends
- Bonus
- Split
- Rights
- Meeting Date
- Purpose
- 12-Nov-24
- Quarterly Results
- 09-Aug-24
- Quarterly Results
- 30-May-24
- Audited Results
- 05-Feb-24
- Quarterly Results
- 09-Nov-23
- Quarterly Results
- 08-Aug-23
- Quarterly Results
- 25-May-23
- Audited Results
- 06-Feb-23
- Quarterly Results
- 08-Nov-22
- Quarterly Results
- 08-Aug-22
- Quarterly Results
- Meeting Date
- Announced on
- Purpose
- 09-Aug-24
- 15-Jul-24
- AGM
- 15-Feb-24
- 12-Jan-24
- POM
- 15-Dec-23
- 10-Nov-23
- AGM
- 14-Dec-23
- 13-Nov-23
- POM
- 18-Aug-22
- 09-May-22
- AGM
- 31-Aug-21
- 08-Jun-21
- AGM
- Announced on
- Record Date
- Ex-Dividend
- Dividend Value
- 29-Aug-22
- 12-Sept-22
- 09-Sept-22
- 1
- 30-Aug-22
- 12-Sept-22
- 09-Sept-22
- 5
- 02-May-22
- 17-May-22
- 13-May-22
- 1
- 03-May-22
- 17-May-22
- 13-May-22
- 1
- 01-Feb-22
- 16-Feb-22
- 15-Feb-22
- 1
- 02-Feb-22
- 16-Feb-22
- 15-Feb-22
- 2
- 08-Jun-21
- 17-Aug-21
- 13-Aug-21
- 1
- 03-Feb-21
- 18-Feb-21
- 17-Feb-21
- 1